Praxis Precision Medicines Competitors

Praxis Precision Medicines (NASDAQ:PRAX) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Praxis Precision Medicines and Biohaven Pharmaceutical, as provided by MarketBeat.

Praxis Precision Medicines currently has a consensus target price of $60.3333, suggesting a potential upside of 138.47%. Biohaven Pharmaceutical has a consensus target price of $96.4545, suggesting a potential upside of 28.95%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Biohaven Pharmaceutical.

Insider and Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Praxis Precision Medicines and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Praxis Precision Medicines and Biohaven Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Summary

Praxis Precision Medicines beats Biohaven Pharmaceutical on 4 of the 7 factors compared between the two stocks.

Praxis Precision Medicines (NASDAQ:PRAX) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Praxis Precision Medicines and Hutchison China MediTech, as provided by MarketBeat.

Praxis Precision Medicines currently has a consensus target price of $60.3333, suggesting a potential upside of 138.47%. Hutchison China MediTech has a consensus target price of $40.00, suggesting a potential upside of 37.03%. Given Praxis Precision Medicines' higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Hutchison China MediTech.

Insider and Institutional Ownership

33.5% of Hutchison China MediTech shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Praxis Precision Medicines and Hutchison China MediTech's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Praxis Precision Medicines and Hutchison China MediTech's revenue, earnings per share (EPS) and valuation.

Praxis Precision Medicines has higher earnings, but lower revenue than Hutchison China MediTech.

Praxis Precision Medicines (NASDAQ:PRAX) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Praxis Precision Medicines and Sage Therapeutics, as provided by MarketBeat.

Praxis Precision Medicines currently has a consensus target price of $60.3333, suggesting a potential upside of 138.47%. Sage Therapeutics has a consensus target price of $87.0625, suggesting a potential upside of 15.06%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Sage Therapeutics.

Profitability

This table compares Praxis Precision Medicines and Sage Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Praxis Precision Medicines and Sage Therapeutics' revenue, earnings per share (EPS) and valuation.

Praxis Precision Medicines has higher earnings, but lower revenue than Sage Therapeutics.

Summary

Praxis Precision Medicines beats Sage Therapeutics on 5 of the 7 factors compared between the two stocks.

Praxis Precision Medicines (NASDAQ:PRAX) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Praxis Precision Medicines and Arena Pharmaceuticals, as provided by MarketBeat.

Praxis Precision Medicines currently has a consensus target price of $60.3333, suggesting a potential upside of 138.47%. Arena Pharmaceuticals has a consensus target price of $92.80, suggesting a potential upside of 37.20%. Given Praxis Precision Medicines' higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Arena Pharmaceuticals.

Insider and Institutional Ownership

89.7% of Arena Pharmaceuticals shares are held by institutional investors. 3.1% of Arena Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Praxis Precision Medicines and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Praxis Precision Medicines and Arena Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Arena Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines.

Summary

Arena Pharmaceuticals beats Praxis Precision Medicines on 4 of the 7 factors compared between the two stocks.

Praxis Precision Medicines (NASDAQ:PRAX) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Praxis Precision Medicines and Emergent BioSolutions, as provided by MarketBeat.

Praxis Precision Medicines currently has a consensus target price of $60.3333, suggesting a potential upside of 138.47%. Emergent BioSolutions has a consensus target price of $113.6667, suggesting a potential upside of 52.63%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Emergent BioSolutions.

Insider and Institutional Ownership

80.2% of Emergent BioSolutions shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Praxis Precision Medicines and Emergent BioSolutions' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Praxis Precision Medicines and Emergent BioSolutions' revenue, earnings per share (EPS) and valuation.

Emergent BioSolutions has higher revenue and earnings than Praxis Precision Medicines.

Summary

Emergent BioSolutions beats Praxis Precision Medicines on 7 of the 9 factors compared between the two stocks.

Praxis Precision Medicines (NASDAQ:PRAX) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Praxis Precision Medicines and Turning Point Therapeutics, as provided by MarketBeat.

Praxis Precision Medicines currently has a consensus target price of $60.3333, suggesting a potential upside of 138.47%. Turning Point Therapeutics has a consensus target price of $153.7143, suggesting a potential upside of 102.52%. Given Praxis Precision Medicines' higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Turning Point Therapeutics.

Insider and Institutional Ownership

81.3% of Turning Point Therapeutics shares are held by institutional investors. 23.2% of Turning Point Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Praxis Precision Medicines and Turning Point Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Praxis Precision Medicines and Turning Point Therapeutics' revenue, earnings per share (EPS) and valuation.